Aymeric Sallin Net Worth

Aymeric Sallin biography

Aymeric Sallin is Independent Director of the Company. Mr. Sallin has served as a member of our Board of Directors since 2008. Mr. Sallin has served as the Chief Executive Officer of NanoDimension, a venture capital firm, since 2002 and is the founder of that firm. Since 2014, Mr. Sallin has served as a strategic advisory board member of the École Polytechnique Fédérale de Lausanne, or EPFL. Since 2002, Mr. Sallin has worked to promote nanotechnology around the world, and has received the NSTI Fellow Award and 2012 EPFL Alumni award for his contribution to the field of nanotechnology. He currently serves as a board member of numerous private companies, including H55, Inc., View, Inc., CROCUS Technology and Tarveda Therapeutics. Mr. Sallin is also a member of the Swiss Academy of Engineering Science. Mr. Sallin received his Master's in Physical Engineering from EPFL in Lausanne, Switzerland. Mr. Sallin's extensive knowledge of our business and the nanomedicine field contributed to our Board of Directors’ conclusion that he should serve as a director of the Company.

What is the salary of Aymeric Sallin?

As the Independent Director of Selecta Biosciences Inc, the total compensation of Aymeric Sallin at Selecta Biosciences Inc is $61,033. There are 7 executives at Selecta Biosciences Inc getting paid more, with Carsten Brunn having the highest compensation of $1,986,500.

How old is Aymeric Sallin?

Aymeric Sallin is 46, he's been the Independent Director of Selecta Biosciences Inc since 2008. There are 13 older and 3 younger executives at Selecta Biosciences Inc. The oldest executive at Selecta Biosciences Inc is Patrick Zenner, 73, who is the Independent Director.

What's Aymeric Sallin's mailing address?

Aymeric's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 65 GROVE STREET, WATERTOWN, MA, 02472.

Insiders trading at Selecta Biosciences Inc

Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit... oraz Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.

What does Selecta Biosciences Inc do?

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat

Selecta Biosciences Inc executives and stock owners

Selecta Biosciences Inc executives and other stock owners filed with the SEC include:

• Carsten Brunn,
  President, Chief Executive Officer, Director
• Lloyd Johnston,
  Chief Operating Officer, Senior Vice President - Research & development
• Dr. Carsten Brunn,
  CEO, Pres & Director
• Dr. Peter G. Traber M.D.,
  Chief Medical Officer
• Patrick Zenner,
  Independent Director
• Timothy Springer,
  Independent Director
• Timothy Barabe,
  Independent Director
• Aymeric Sallin,
  Independent Director
• Scott Myers,
  Independent Director
• Carrie Cox,
  Independent Chairman of the Board
• Lee Stern,
  IR Contact Officer
• Goran Ando,
  Independent Director
• Bradford Dahms,
  Chief Financial Officer, Principal Accounting Officer
• Takashi Kishimoto,
  Chief Scientific Officer
• Kristen Baldwin,
  Chief People Officer
• Dr. Takashi Kei Kishimoto Ph.D.,
  Chief Scientific Officer
• Dr. Lloyd Johnston,
  COO and Sr. VP of R&D
• Kevin Tan,
  Chief Financial Officer
• Ann K. Donohue,
  VP of Fin., Interim Principal Financial Officer & Principal Accounting Officer
• Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D.,
  Co-Founder and Co-Chair of the Scientific Advisory Board
• Omid Farokhzad,
  Director
• Peter Barton Hutt,
  Director
• Edwin M Jr Kania,
  Director
• Peter Keller,
  Chief Business Officer
• Advisors Llc Orbi Med Capit...,
  
• Rusnano,
  10% owner
• Carl L Gordon,
  Director
• Capital I2 Bf Netherlands, ...,
  
• University Partners Ii, L.P...,
  
• Management Ltd Nanodimensio...,
  
• Partners, Llc Leukon Invest...,
  
• Venture Management Co. V, L...,
  
• Ventures Fund 2007, L.P.Fla...,
  
• Earl Sands,
  Chief Medical Officer
• David Siewers,
  Chief Financial Officer
• David Abraham,
  CCO, GC and Corp. Sec.
• Nishan M De Silva,
  Director
• Werner Cautreels,
  President and CEO
• Amir Nashat,
  Director
• John Harold Leaman,
  CFO, Treas. & Hd Corp Strategy
• Stephen Smolinski,
  Chief Commercial Officer
• Elona Kogan,
  General Counsel
• Peter G Traber,
  Chief Medical Officer
• Alison D. Schecter,
  Chief Medical Officer
• Kevin Tan,
  Chief Financial Officer
• Blaine Davis,
  Chief Financial Officer